Models for Implementing Buprenorphine Treatment in the VHA

Federal Practitioner. 2009 May;26(5):48-57

November 16, 2020|Federal Practitioner

Adam J. Gordon, MD, MPH;Cynthia M.A. Geppert, MD, PhD, MPH;Andrew Saxon, MD;Ann Cotton, PsyD;Timothy Bondurant, MD;Margaret Krumm, BA;Mary Pat Acquaviva, PA;Jodie Trafton, PhD

Although proven as a cost-effective treatment in VHA settings, buprenorphine currently is underutilized by VA practitioners. These authors review the drug’s advantages and describe how some VA programs are employing it successfully

Download Article